ProfessionalHybridActive

Certificate in Psychedelic-Assisted Therapies and Research

A professional certificate program in psychedelic-assisted therapies and research offered by CIIS. It covers clinical and research foundations including pharmacology, research design, therapist competencies, and cultural and historical context.

Provider

English

Details

150 hours
Next cohort: Jun 1, 2026

Enrollment

Upcoming Cohort

Start date: June 1, 2026

Application deadline: June 1, 2026

Course Overview

The Certificate in Psychedelic-Assisted Therapies and Research is a professional program from the California Institute for Integral Studies (CIIS) Center for Psychedelic Therapies and Research. It is designed for professionals working in mental health, medicine, law, clergy, and chaplaincy roles. The curriculum includes intellectual, personal, and applied learning in psychedelic-assisted and entactogen-assisted psychotherapy research and clinical work. Topics listed on the source page include pharmacology of psychoactive substances, research design, therapist and facilitator competencies, the global history of psychoactive plant use, and cultural competencies. The program emphasizes clinical work with MDMA and psilocybin, with additional coursework on ketamine-assisted psychotherapy. It is described as a hybrid course with an estimated 150 hours of workload.

Who is this for?

Clinicians, therapists, researchers, clergy, and professionals in licensed mental health, medical, and legal professions.

Prerequisites

Open to professionals in licensed mental health, medical, and legal professions, as well as ordained or commissioned clergy and chaplains.

About the Provider

Fluence is a psychedelic therapy education company co-founded by psychologists Dr. Ingmar Gorman and Dr. Elizabeth Nielson, offering continuing education courses and a Certificate in Psychedelic Therapy and Integration for licensed therapists and advanced graduate students. Having trained 8,000+ clinicians, Fluence draws on its founders' direct experience in FDA-approved Phase 3 clinical trials of MDMA- and psilocybin-assisted therapies.

View Fluence profile

Course Details